Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:INVA NASDAQ:MNKD NASDAQ:NVAX NASDAQ:VSTM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINVAInnoviva$18.63+2.5%$19.95$16.67▼$22.00$1.14B0.38785,688 shs984,244 shsMNKDMannKind$3.75-0.8%$3.91$3.51▼$7.63$1.15B1.022.42 million shs2.54 million shsNVAXNovavax$6.56-1.4%$6.94$5.01▼$15.22$1.08B2.694.84 million shs5.43 million shsVSTMVerastem$6.08-1.5%$5.56$2.10▼$9.10$339.04M0.712.23 million shs2.02 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINVAInnoviva+2.53%-0.48%-3.97%-0.48%-1.11%MNKDMannKind-0.79%-7.64%+3.59%-25.00%-34.90%NVAXNovavax-1.35%-12.18%-2.96%+2.34%-48.79%VSTMVerastem-1.46%-0.98%+25.36%-18.17%+133.85%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationINVAInnoviva4.1694 of 5 stars3.51.00.04.22.31.71.9MNKDMannKind3.2911 of 5 stars3.63.00.00.01.91.71.9NVAXNovavax4.5925 of 5 stars3.13.00.04.72.50.83.1VSTMVerastem2.4638 of 5 stars3.51.00.00.02.82.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceINVAInnoviva 3.00Buy$40.33116.50% UpsideMNKDMannKind 3.25Buy$9.86162.86% UpsideNVAXNovavax 2.25Hold$15.86141.72% UpsideVSTMVerastem 3.00Buy$13.38119.98% UpsideCurrent Analyst Ratings BreakdownLatest VSTM, MNKD, NVAX, and INVA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/23/2025MNKDMannKindRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$10.00 ➝ $8.007/22/2025NVAXNovavaxBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$10.00 ➝ $9.007/16/2025MNKDMannKindHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$9.007/14/2025INVAInnovivaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$40.007/14/2025INVAInnovivaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$40.007/11/2025INVAInnovivaCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$26.006/25/2025VSTMVerastemRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform ➝ Moderate Buy$16.00 ➝ $12.006/17/2025NVAXNovavaxCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSell$6.005/19/2025NVAXNovavaxB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/9/2025NVAXNovavaxJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderweight ➝ Underweight$9.00 ➝ $7.005/9/2025VSTMVerastemHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$10.00 ➝ $14.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookINVAInnoviva$358.71M3.26$3.52 per share5.30$11.03 per share1.69MNKDMannKind$285.50M3.99$0.14 per share27.24($0.29) per share-12.93NVAXNovavax$1.21B0.87N/AN/A($3.89) per share-1.69VSTMVerastem$10M33.41N/AN/A($0.65) per share-9.35Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateINVAInnoviva$23.39M-$1.01N/A12.02N/A-16.15%15.77%8.41%N/AMNKDMannKind$27.59M$0.1037.5016.30N/A10.12%-32.41%10.85%8/6/2025 (Estimated)NVAXNovavax-$187.50M$2.652.4882.000.0838.14%-115.51%29.99%8/6/2025 (Estimated)VSTMVerastem-$130.64M-$3.20N/AN/AN/AN/A-2,003.62%-127.97%8/7/2025 (Estimated)Latest VSTM, MNKD, NVAX, and INVA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025VSTMVerastem-$0.64N/AN/AN/A$6.01 millionN/A8/6/2025Q2 2025MNKDMannKind$0.04N/AN/AN/A$77.82 millionN/A8/6/2025Q2 2025NVAXNovavax-$0.12N/AN/AN/A$149.19 millionN/A5/13/2025Q1 2025VSTMVerastem-$0.72-$0.96-$0.24-$0.96$0.10 millionN/A5/8/2025Q1 2025MNKDMannKind$0.03$0.04+$0.01$0.04$75.86 million$78.35 million5/8/2025Q1 2025NVAXNovavax$0.71$2.93+$2.22$2.93$204.08 million$666.66 million5/7/2025Q1 2025INVAInnovivaN/A$0.25N/A-$0.74N/A$88.63 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthINVAInnovivaN/AN/AN/AN/AN/AMNKDMannKindN/AN/AN/AN/AN/ANVAXNovavaxN/AN/AN/AN/AN/AVSTMVerastemN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioINVAInnoviva0.402.482.30MNKDMannKindN/A2.362.11NVAXNovavaxN/A2.062.03VSTMVerastemN/A3.503.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipINVAInnoviva99.12%MNKDMannKind49.55%NVAXNovavax53.04%VSTMVerastem88.37%Insider OwnershipCompanyInsider OwnershipINVAInnoviva2.25%MNKDMannKind2.70%NVAXNovavax1.00%VSTMVerastem2.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableINVAInnoviva10062.78 million61.36 millionOptionableMNKDMannKind400303.93 million295.73 millionOptionableNVAXNovavax1,990161.97 million160.35 millionOptionableVSTMVerastem5054.95 million53.80 millionOptionableVSTM, MNKD, NVAX, and INVA HeadlinesRecent News About These CompaniesVerastem (VSTM) Projected to Post Quarterly Earnings on ThursdayAugust 1 at 5:26 AM | marketbeat.comEarnings Preview: Verastem (VSTM) Q2 Earnings Expected to DeclineJuly 31 at 11:06 AM | zacks.comVerastem (NASDAQ:VSTM) Share Price Passes Above Two Hundred Day Moving Average - Time to Sell?July 31 at 4:43 AM | marketbeat.comVerastem Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025July 29, 2025 | businesswire.comVerastem Inc. (VSTM) Stock Price Today - WSJJuly 27, 2025 | wsj.comVerastem Oncology gets FDA fast track status for cancer drugJuly 24, 2025 | msn.comVerastem Oncology Granted Fast Track Designation for VS-7375 for the Treatment of KRAS G12D-mutated Locally Advanced or Metastatic Pancreatic CancerJuly 24, 2025 | finance.yahoo.comVerastem, Inc. (NASDAQ:VSTM) Given Average Rating of "Buy" by BrokeragesJuly 23, 2025 | marketbeat.comAIGH Capital Management LLC Has $14.10 Million Stake in Verastem, Inc. (NASDAQ:VSTM)July 22, 2025 | marketbeat.comVerastem’s Promising KRAS G12D Inhibitor Study: A Potential Game-Changer in Cancer TreatmentJuly 18, 2025 | tipranks.comVerastem: The Market Is Ignoring The ProgressJuly 16, 2025 | seekingalpha.comVerastem stock rises after LGSOC treatment data published in medical ...July 13, 2025 | investing.comVerastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial ...July 11, 2025 | gurufocus.comVerastem (VSTM) Reports Promising Phase 2 Trial Results in Ovarian Cancer | VSTM Stock NewsJuly 11, 2025 | gurufocus.comVerastem stock rises after LGSOC treatment data published in medical journalJuly 11, 2025 | in.investing.comVerastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical OncologyJuly 11, 2025 | businesswire.comVerastem, Inc. (VSTM) - Yahoo FinanceJuly 9, 2025 | finance.yahoo.comVerastem KRAS-Mutant Ovarian Cancer Treatment Activity Affirmed in Investigator-Initiated StudyJuly 8, 2025 | precisionmedicineonline.comPVerastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 8, 2025 | businesswire.comBTIG Remains a Buy on Verastem (VSTM)July 4, 2025 | theglobeandmail.comVerastem’s Phase 3 Study on Avutometinib and Defactinib: A Potential Game-Changer for Ovarian Cancer TreatmentJuly 4, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVSTM, MNKD, NVAX, and INVA Company DescriptionsInnoviva NASDAQ:INVA$18.63 +0.46 (+2.53%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$18.63 0.00 (0.00%) As of 08/1/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.MannKind NASDAQ:MNKD$3.75 -0.03 (-0.79%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$3.80 +0.06 (+1.47%) As of 08/1/2025 06:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.Novavax NASDAQ:NVAX$6.56 -0.09 (-1.35%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$6.60 +0.04 (+0.53%) As of 08/1/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.Verastem NASDAQ:VSTM$6.08 -0.09 (-1.46%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$6.10 +0.03 (+0.41%) As of 08/1/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Why Bloom Energy Stock Could Break to New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
